Program
Please note that this meeting will take place as an in-person event in Bellevue and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.
CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.
All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.
*-Short talk from proffered abstract
THURSDAY, NOVEMBER 14
FRIDAY, NOVEMBER 15
- Plenary Session 1: Deregulation of RNA in Cancer
- Plenary Session 2: Design of mRNA Drugs
- Plenary Session 3: Interaction between RNA Drugs and the Immune System
SATURDAY, NOVEMBER 16
- Plenary Session 4: RNA Delivery
- Plenary Session 5: RNAs as Drivers and Targets in Cancer
- Plenary Session 6: Small RNA Therapeutics
SUNDAY, NOVEMBER 17
WELCOME AND OPENING KEYNOTE
6-7 p.m.
- Howard Y. Chang, Stanford University, Stanford, California
- Joshua T. Mendell, University of Texas Southwestern Medical Center, Dallas, Texas
- Anastasia Khvorova, University of Massachusetts Chan Medical School, Worcester, Massachusetts
- Narry Kim, Seoul National University, Seoul, Korea
Opening Keynote Address
7-8:30 p.m.
- Davide Ruggero, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Continental Breakfast
7-8 a.m.
Plenary Session 1: Deregulation of RNA in cancer
8-10 a.m.
- Hani Goodarzi, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
- Robert Bradley, Fred Hutchinson Cancer Center, Seattle, Washington
- Anna Nam, Weill Cornell Medicine, New York, New York
Plenary Session 2: Design of mRNA drugs
10:30 a.m. – 12:30 p.m.
- Kevin Weeks, UNC Chapel Hill, Durham, North Carolina
- Giles Besin, Orbital Therapeutics, Cambridge, Massachusetts
- Narry Kim, Seoul National University, Seoul, Korea
Lunch Break on own
12:30-2:30 p.m.
Plenary Session 3: Interaction between RNA drugs and the immune system
2:30-4:30 p.m.
- Sun Hur, Harvard Medical School, Boston, Massachusetts
- Ling-Ling Chen, Shanghai Institute of Biochemistry and Cell Biology, Shanghai, China
- Serena Silver, Accent Therapeutics, Boston, Massachusetts
Poster Session A (with light refreshments)
4:30-7 p.m.
Continental Breakfast
7-8 a.m.
Plenary Session 4: RNA delivery
8-10 a.m.
- Aditya Raguram, Massachusetts Institute of Technology, Cambridge, Massachusetts
- Additional speaker to be announced
Break
10-10:30 a.m.
Plenary Session 5: RNAs as drivers and targets in cancer
10:30 a.m. – 12:30 p.m.
- Josh Mendell, University of Texas Southwestern Medical Center, Dallas, Texas
- Nadya Dimitrova, Yale University, New Haven Connecticut
- Howard Chang, Stanford University, Stanford, California
Lunch Break (lunch on your own)
12:30-2:30 p.m.
Plenary Session 6: Small RNA therapeutics
2:30-4:30 p.m.
- Anastasia Khvorova, University of Massachusetts Chan Medical School, Worcester, Massachusetts
- Muthiah Manoharan, Alnylam Pharmaceuticals, Cambridge, Massachusetts
- Andrew Denker, Flamingo, Philadelphia, Pennsylvania
Poster Session B (with light refreshments)
4:30-7 p.m.
Continental Breakfast
7-8 a.m.
Plenary Session 7: RNA for Cancer immunotherapy
8-10 a.m.
- Vinod Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York
- Crystal Mackall, Stanford University, Stanford, California
- Grace Chen, Yale University, New Haven, Connecticut
Break
10-10:30 a.m.
Plenary Session 8: Emerging RNA Technologies
10:30 a.m.- 12:30 p.m.
- Xiaojing Gao, Stanford University, Stanford, California
- Matthew Disney, Scripps Research Institute, San Diego, California
- Manjunath Ramarao, Atomic AI, Stanford, California
Closing Remarks
12:30-12:45 p.m.